Biotech startup Cervance Inc. could earn more than $1 billion via a collaboration with drugmaker Merck & Company to research potential treatments for Alzheimer’s disease. This a fledgling sector. Although victims of the disease are growing quickly, there have been no effective new treatments that have come to market in more than a decade. “Hopefully the tide is turning,” Cerevance CEO Craig Thompson, told the Wall Street Journal. Cerevance gathers brain tissue from brain banks, or centers that obtain brains from organ donors. It then examines brain tissue to identify brain diseases and metrics such as what genes are over- or under-active. Regular readers of my blog know that both my father and my grandmother had this debilitating disease when they passed away. There are some great people at the Monterey Chapter of Alzheimer’s Association in Ryan Ranch, or you can call their 24-hour hotline at 1-800-272-3900.